SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Tenacious Labs acquires first CBD brand in Press Pause takeover

    By

    London-based firm Tenacious Labs has embarked on a round of acquisitions as it seeks to expand.

    The company has announced it has taken over Denver CBD brand Press Pause and is set to announce further moves this week.

    According to a statement, the company has a strategy to acquire established brands and become ‘the leading consumer-centric cannabinoid group’.

    Companies House documents show Tenacious Labs and its associated holdings company were set up in September 2020.

    The company is led by chief executive Nicholas Morland and chief commercial officer Adrian Clarke, who has family ties to the Bacardi drinks company.

    In a statement, Morland said: “Our first acquisition, this is a major milestone in our strategy of building and developing a global portfolio of consumer cannabinoid brands.

    “It brings an established US brand to the UK as the market enters its next phase of growth and consolidation.”

    Clarke said: “As consumer attitudes to cannabinoids change, we see enormous potential for value creation within the industry.

    “We are calling on UK regulators to unite the industry’s stakeholders and build a transparent framework that not only protects consumers, but also allows the industry to flourish for years to come.”

    10 June 2026 · Berlin Sales end May 29

    European Cannabis
    Insights Summit

    From €216

    200+ industry leaders. Exclusive German market data. A half-day briefing for B2B operators in Europe's most important emerging cannabis market.

    Sean Seddon

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free